

Consolidated Financial Statements for the First Quarter of the Fiscal Year Ending March 31, 2026

August 5, 2025

The financial statements herein have been prepared in accordance with accounting principles and practices widely accepted in Japan, and are for reference purposes only.

MEDIPAL HOLDINGS CORPORATION

Stock exchange listing: Tokyo Stock Exchange

Stock exchange code: 7459

Website: <https://www.medipal.co.jp/english/>

Representative: Shuichi Watanabe, Representative Director, President and CEO

Contact: Yuji Sakon, Managing Director, General Manager of the Administration Division

Telephone: +81-3-3517-5171

Start of distribution of dividends (scheduled): —

Supplementary materials for the financial statements: Yes

Presentation to explain the financial statements: No

(All amounts are rounded down to the nearest million yen.)

1. Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2026 (April 1, 2025, to June 30, 2025)

(1) Sales and Profits (The year-on-year change refers to the same period of the previous fiscal year.)

	Net sales (Millions of yen)	Year-on-year change (%)	Operating profit (Millions of yen)	Year-on-year change (%)	Ordinary profit (Millions of yen)	Year-on-year change (%)
Three months ended June 30, 2025	945,159	3.9	14,053	5.8	18,234	7.8
Three months ended June 30, 2024	909,317	2.5	13,283	7.1	16,916	1.4

Note: Comprehensive income decreased by 35.1% year on year to ¥9,804 million in the three months ended June 30, 2025, and by 33.0% year on year to ¥15,102 million in the three months ended June 30, 2024.

	Profit attributable to owners of parent (Millions of yen)	Year-on-year change (%)	Earnings per share (Yen)	Earnings per share (diluted) (Yen)
Three months ended June 30, 2025	9,586	6.4	46.17	—
Three months ended June 30, 2024	9,008	(19.5)	42.96	—

(2) Financial Position

	Total assets (Millions of yen)	Net assets (Millions of yen)	Net worth ratio* (%)	Net assets per share (Yen)
As of June 30, 2025	1,850,979	756,972	33.3	2,980.53
As of March 31, 2025	1,824,984	757,947	33.9	2,979.39

Reference: * Calculated based on net worth of ¥616,579 million as of June 30, 2025, and ¥619,564 million as of March 31, 2025.

2. Dividend Payments

	Dividends per share (Yen)				
	1st quarter	2nd quarter	3rd quarter	Year-end	Full year
Paid for the year ended March 31, 2025	—	30.00	—	32.00	62.00
Paid for the year ending March 31, 2026	—				
Planned for the year ending March 31, 2026		32.00		32.00	64.00

Note: Revisions to the planned dividend payments announced on May 13, 2025: None

3. Forecast of Consolidated Financial Results for the Fiscal Year Ending March 31, 2026 (April 1, 2025, to March 31, 2026)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of the parent		Earnings per share
	(Millions of yen)	YoY change	(Millions of yen)	YoY change	(Millions of yen)	YoY change	(Millions of yen)	YoY change	(Yen)
Full fiscal year	3,785,000	3.1%	52,000	(6.5%)	69,000	5.7%	34,500	(14.3%)	167.28

Note: Revisions to the most recent forecast announced on May 13, 2025: None

Pursuant to a decision by the Board of Directors in a meeting held on May 13, 2025, the Company plans to acquire its own shares in the fiscal year ending March 31, 2026. The forecast of earnings per share, above, was calculated in consideration of the impact of this planned share buyback.

Notes

- (1) Significant changes in scope of consolidation during the three months ended June 30, 2025: Yes
Subsidiaries added to the scope of consolidation: None
Subsidiaries removed from the scope of consolidation: 1 (MVC CO., LTD.)
Note: MVC CO., LTD., was removed from the scope of consolidation because it was absorbed by the Company's wholly owned subsidiary, ATOL CO., LTD. (the surviving company of the merger) effective from April 1, 2025.
- (2) Application of accounting methods specific to the preparation of the quarterly consolidated financial statements: None
- (3) Changes in accounting policies and estimates, and restatements of accounting estimates
(a) Changes in accounting policies due to revisions of accounting standards: None
(b) Changes in accounting policies other than (a) above: None
(c) Changes in accounting estimates: None
(d) Restatements: None

- (4) Number of shares issued and outstanding (common stock)

(a) Number of shares issued at the end of the period (including treasury stock)	As of June 30, 2025	219,226,042	As of March 31, 2025	219,226,042
(b) Number of treasury shares at the end of the period	As of June 30, 2025	12,356,631	As of March 31, 2025	11,275,805
(c) Average number of shares during the period	April 1 to June 30, 2025	207,628,161	April 1 to June 30, 2024	209,722,699

* Non-mandatory review of the Japanese-language originals of the consolidated quarterly financial statements herein by certified public accountants or an audit firm: Completed

* Disclaimer Regarding Forward-Looking Statements

The forecast of consolidated financial results is based on information at the time of the publication of this report. Results may differ from the forecast amounts owing to a wide range of factors.

Availability of Supplemental Materials Covering the Financial Results

Supplemental materials are made available in the "IR Library" section of the Company's website.

Table of Contents

1. Overview of Financial Results	2
(1) Overview of Results of Operations	2
(2) Overview of Financial Position	5
2. Quarterly Consolidated Financial Statements	6
(1) Quarterly Consolidated Balance Sheets	6
(2) Quarterly Consolidated Statements of Income and Quarterly Consolidated Statements of Comprehensive Income	8
Quarterly Consolidated Statements of Income	8
Quarterly Consolidated Statements of Comprehensive Income	9
(3) Notes to the Quarterly Consolidated Financial Statements	10
Segment Results	10
Notes in the Event of Significant Changes in Shareholders' Equity	10
Notes Regarding Assumptions of Going Concern	10
Notes Regarding Quarterly Consolidated Statements of Cash Flows	10

1. Overview of Financial Results

(1) Overview of Results of Operations

Consolidated financial results for the first three months ended June 30, 2025, are as follows.

(Millions of yen, rounded down to the nearest million)

	Three months ended June 30, 2024	Three months ended June 30, 2025	Difference	YoY change
Net sales	909,317	945,159	+35,842	+3.9%
Gross profit	62,598	64,677	+2,079	+3.3%
Percentage of net sales	6.88%	6.84%	(0.04pp)	
Selling, general and administrative expenses	49,314	50,624	+1,309	+2.7%
Percentage of sales	5.42%	5.36%	(0.07pp)	
Selling, general and administrative expenses excluding (i) and (ii) below	48,760	50,032	+1,271	+2.6%
(i) Business investment and other expenses	39	8	(30)	(77.4%)
(ii) Amortization of goodwill and intangible assets*	514	582	+68	+13.4%
Operating profit	13,283	14,053	+769	+5.8%
Percentage of net sales	1.46%	1.49%	+0.03pp	
Operating profit excluding (i) and (ii) above	13,837	14,645	+807	+5.8%
Ordinary profit	16,916	18,234	+1,317	+7.8%
Net extraordinary income	450	431	(18)	(4.1%)
Profit before income taxes	17,367	18,666	+1,299	+7.5%
Profit attributable to owners of parent	9,008	9,586	+577	+6.4%

* Amortization of goodwill and intangible assets associated with growth investments set forth in the 2027 MEDIPAL Medium-Term Vision

Net sales

Net sales grew by ¥35,842 million (3.9%) year on year to ¥945,159 million.

- All business segments posted net sales growth compared with the same period of the previous fiscal year, with increases of ¥22,117 million (3.8%) in the Prescription Pharmaceutical Wholesale Business segment, ¥13,132 million (4.3%) in the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business segment, and ¥558 million (1.9%) in the Animal Health Products and Food Processing Raw Materials Wholesale and Related Business segment.

Operating profit

Operating profit rose by ¥769 million (5.8%) year on year to ¥14,053 million.

- Gross profit increased by ¥2,079 million (3.3%) on the back of net sales growth. The ratio of gross profit to net sales was 6.84%, down 0.04 of a percentage point from 6.88% in the same period of the previous fiscal year.
- Selling, general and administrative (SG&A) expenses increased by ¥1,309 million (2.7%) year on year, mainly due to rising logistics expenses and proactive investment in human resources in the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business segment. The ratio of SG&A expenses to net sales was 5.36%, improving by 0.07 of a percentage point from 5.42% in the same period of the previous fiscal year.

Ordinary profit

Ordinary profit increased by ¥1,317 million (7.8%) year on year to ¥18,234 million.

- The rise in ordinary profit reflected the growth in operating profit as well as an increase in non-operating income of ¥548 million, which was primarily the result of a gain on investments in affiliated companies (recorded as “share of profit of entities accounted for using equity method”).

Profit attributable to owners of parent

Profit attributable to owners of parent increased by ¥577 million (6.4%) year on year to ¥9,586 million.

- Net extraordinary income came to ¥431 million, down ¥18 million compared with the same period of the previous fiscal year. Among the main factors underlying this result, a gain on sale of investment securities of ¥886 million and compensation income of ¥478 million were recorded under extraordinary income, resulting in an increase of ¥875 million in total extraordinary income, while ¥922 million in expenses for business restructuring associated with the logistics operations of the Prescription Pharmaceutical Wholesale Business was recorded under extraordinary losses.

Prescription Pharmaceutical Wholesale Business Segment

(Millions of yen, rounded down to the nearest million)

	Three months ended June 30, 2024	Three months ended June 30, 2025	Difference	YoY change
Net sales	577,884	600,001	+22,117	+3.8%
Gross profit	36,061	36,786	+724	+2.0%
Percentage of net sales	6.24%	6.13%	(0.11pp)	
Selling, general and administrative expenses	31,025	31,253	+228	+0.7%
Percentage of net sales	5.37%	5.21%	(0.16pp)	
Selling, general and administrative expenses excluding (i) and (ii) below	30,985	31,175	+189	+0.6%
(i) Business investment and other expenses	39	8	(30)	(77.4%)
(ii) Amortization of goodwill*	—	68	+68	—
Operating profit	5,036	5,533	+496	+9.9%
Percentage of net sales	0.87%	0.92%	+0.05pp	
Operating profit excluding (i) and (ii) above	5,076	5,611	+534	+10.5%

* Amortization of goodwill associated with growth investments set forth in the 2027 MEDIPAL Medium-Term Vision

Net sales

Net sales increased by ¥22,117 million (3.8%) year on year to ¥600,001 million.

- Despite falling demand for therapeutic drugs and diagnostic reagents for COVID-19 amid declining case numbers, higher sales from drug dispensary sales channels and measures for stepping up marketing of products designated as having potential for growth contributed to the increase in net sales.

Operating profit

Operating profit rose by ¥496 million (9.9%) year on year to ¥5,533 million.

- Gross profit increased by ¥724 million (2.0%) to ¥36,786 million, mainly as a result of the increase in net sales. The ratio of gross profit to net sales was 6.13%, down 0.11 of a percentage point from 6.24% in the same period of the previous fiscal year. This reflected changes in the product mix as sales of diagnostic reagents have slowed amid declining cases of COVID-19.
- SG&A expenses edged up ¥228 million (0.7%) year on year to ¥31,253 million, partly due to the impact of making PreMedica Inc. (headquarters: Minato-ku, Tokyo) a wholly owned subsidiary in the first quarter of the previous fiscal year. Nevertheless, the ratio of SG&A expenses to net sales improved by 0.16 of a percentage point to 5.21%.

Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business Segment

(Millions of yen, rounded down to the nearest million)

	Three months ended June 30, 2024	Three months ended June 30, 2025	Difference	YoY change
Net sales	302,914	316,047	+13,132	+4.3%
Gross profit	22,349	23,686	+1,336	+6.0%
Percentage of net sales	7.38%	7.49%	+0.12pp	
Selling, general and administrative expenses	14,920	16,062	+1,141	+7.7%
Percentage of net sales	4.93%	5.08%	+0.16pp	
Operating profit	7,428	7,623	+194	+2.6%
Percentage of net sales	2.45%	2.41%	(0.04pp)	

Net sales

Net sales rose by ¥13,132 million (4.3%) year on year to ¥316,047 million.

- Although consumers tended to economize amid rising prices of goods and services, this business concluded wholesale agreements and applied consumer purchasing data in sales activities to clearly identify changes in purchasing behavior associated with growing awareness of health and demand for leisure outings. It also expanded its lineups of high value-added products, particularly cosmetics. As a result, the business kept sales volume in line with the previous year and increased product selling prices, thereby boosting net sales.

Operating profit

Operating profit totaled ¥7,623 million, up ¥194 million (2.6%) year on year.

- Gross profit increased by ¥1,336 million (6.0%) to ¥23,686 million, backed by net sales growth and expanded lineups of high value-added products. The ratio of gross profit to net sales came to 7.49%, an increase of 0.12 of a percentage point from 7.38% in the same period of the previous fiscal year.
- SG&A expenses rose by ¥1,141 million (7.7%) to ¥16,062 million, mainly as a result of rising logistics expenses and proactive investment in human resources. The ratio of SG&A expenses to net sales improved by 0.16 of a percentage point to 5.08%.

Animal Health Products and Food Processing Raw Materials Wholesale and Related Business Segment

(Millions of yen, rounded down to the nearest million)

	Three months ended June 30, 2024	Three months ended June 30, 2025	Difference	YoY change
Net sales	29,545	30,103	+558	+1.9%
Gross profit	4,199	4,219	+19	+0.5%
Percentage of sales	14.21%	14.02%	(0.20pp)	
Selling, general and administrative expenses	3,514	3,453	(61)	(1.7%)
Percentage of sales	11.90%	11.47%	(0.42pp)	
Selling, general and administrative expenses excluding the following:	3,000	2,939	(61)	(2.0%)
Amortization of goodwill and intangible assets*	514	514	—	—
Operating profit	684	766	+81	+11.9%
Percentage of sales	2.32%	2.54%	+0.23pp	
Operating profit excluding the above amortization	1,198	1,280	+81	+6.8%

* Amortization of goodwill and intangible assets associated with growth investments set forth in the 2027 MEDIPAL Medium-Term Vision

Net sales

Net sales increased by ¥558 million (1.9%) year on year to ¥30,103 million.

- The Animal Health Products Wholesale Business boosted its sales by actively releasing new products and expanding its partnerships with manufacturers, despite the negative impact of changes in product distribution in the companion animal health products industry, specifically the direct sale of certain pet foods by their manufacturers. In the livestock and fish farming industry, although market price competition has been intensifying, sales were up thanks to rising demand for fish vaccines. The Food Processing Raw Materials Wholesale and Related Business also increased its sales by creating new business opportunities and expanded sales in the chemical products market.

Definition of Terms:

* Companion animal: An animal that has a companion-like presence and a close relationship with humans in daily life.

Operating profit

Operating profit totaled ¥766 million, up ¥81 million (11.9%) year on year.

- Gross profit increased by ¥19 million (0.5%) to ¥4,219 million. The ratio of gross profit to sales came to 14.02%, down 0.20 of a percentage point from 14.21% in the same period of the previous fiscal year. Among the underlying factors of this result, the Animal Health Products Wholesale Business and the Food Processing Raw Materials Wholesale and Related Business faced increasingly tough price competition.
- SG&A expenses decreased by ¥61 million (1.7%) to ¥3,453 million, and the ratio of these expenses to net sales improved by 0.42 of a percentage point to 11.47%. This was mainly the result of lower personnel

expenses in the Animal Health Products Wholesale Business and the Food Processing Raw Materials Wholesale and Related Business.

Note: Segment sales include inter-segment transactions.

(2) Overview of Financial Position

Assets

As of June 30, 2025, total assets amounted to ¥1,850,979 million, an increase of ¥25,995 million from the end of the previous fiscal year.

Current assets rose by ¥27,246 million from the end of the previous fiscal year to ¥1,309,993 million. This was mainly due to increases of ¥41,263 million in notes and accounts receivable – trade and ¥3,382 million in merchandise and finished goods, offsetting a decrease in cash and deposits of ¥15,375 million.

Non-current assets decreased by ¥1,251 million from the end of the previous fiscal year to ¥540,986 million. Main factors underlying this result included a decrease in investment securities of ¥2,570 million.

Liabilities

As of June 30, 2025, total liabilities stood at ¥1,094,006 million, an increase of ¥26,969 million from the end of the previous fiscal year.

Current liabilities increased by ¥29,706 million from the end of the previous fiscal year to ¥1,039,153 million, mainly due to an increase in notes and accounts payable–trade of ¥35,342 million.

Non-current liabilities decreased by ¥2,737 million from the end of the previous fiscal year to ¥54,852 million, mainly as a result of a decrease in deferred tax liabilities of ¥1,324 million (included in the “other” line item under “non-current liabilities”).

Net assets

As of June 30, 2025, net assets totaled ¥756,972 million, a decrease of ¥974 million from the end of the previous fiscal year.

Shareholders’ equity increased by ¥448 million from the end of the previous fiscal year to ¥563,734 million. This mainly reflected an increase in retained earnings of ¥2,932 million and acquisitions of treasury shares amounting to ¥2,483 million.

Accumulated other comprehensive income decreased by ¥3,432 million from the end of the previous fiscal year to ¥52,844 million, mainly due to a decrease in valuation difference on available-for-sale securities of ¥2,837 million.

Non-controlling interests increased by ¥2,010 million from the end of the previous fiscal year to ¥140,391 million, mainly due to an increase in net assets held by PALTAC Corporation.

2. Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance Sheets

(Millions of yen, rounded down to the nearest million)

	As of March 31, 2025	As of June 30, 2025
ASSETS		
Current assets		
Cash and deposits	261,407	246,032
Notes and accounts receivable – trade	763,541	804,804
Merchandise and finished goods	178,100	181,483
Other	79,739	77,713
Allowance for doubtful accounts	(42)	(41)
Total current assets	1,282,746	1,309,993
Non-current assets		
Property, plant and equipment:		
Buildings and structures, net	103,180	104,771
Land	117,285	117,284
Other, net	48,098	45,510
Total property, plant and equipment	268,564	267,567
Intangible assets		
Goodwill	13,150	12,818
Customer-related intangible assets	16,392	16,076
Other	10,356	10,204
Total intangible assets	39,898	39,100
Investments and other assets		
Investment securities	199,078	196,507
Other	35,341	38,448
Allowance for doubtful accounts	(644)	(637)
Total investments and other assets	233,774	234,318
Total non-current assets	542,237	540,986
Total assets	1,824,984	1,850,979

(Millions of yen, rounded down to the nearest million)

	As of March 31, 2025	As of June 30, 2025
LIABILITIES		
Current liabilities		
Notes and accounts payable – trade	932,474	967,817
Income taxes payable	13,329	9,820
Provision for bonuses	7,854	5,617
Provision for loss on disposal of fixed assets	167	167
Provision for loss on Anti-Monopoly Act	2,233	2,233
Other	53,387	53,497
Total current liabilities	1,009,447	1,039,153
Non-current liabilities		
Retirement benefit liability	16,057	16,004
Other	41,532	38,847
Total non-current liabilities	57,590	54,852
Total liabilities	1,067,037	1,094,006
NET ASSETS		
Shareholders' equity		
Share capital	22,398	22,398
Capital surplus	100,010	100,010
Retained earnings	463,071	466,003
Treasury shares	(22,193)	(24,677)
Total shareholders' equity	563,286	563,734
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	66,060	63,222
Deferred gains or losses on hedges	(37)	(26)
Revaluation reserve for land	(13,518)	(13,518)
Foreign currency translation adjustment	2,646	2,160
Remeasurements of defined benefit plans	1,126	1,006
Total accumulated other comprehensive income	56,277	52,844
Share acquisition rights	1	1
Non-controlling interests	138,381	140,391
Total net assets	757,947	756,972
Total liabilities and net assets	1,824,984	1,850,979

(2) Quarterly Consolidated Statements of Income and Quarterly Consolidated Statements of Comprehensive Income
Quarterly Consolidated Statements of Income

(Millions of yen, rounded down to the nearest million)

	Three months ended June 30, 2024	Three months ended June 30, 2025
Net sales	909,317	945,159
Cost of sales	846,718	880,481
Gross profit	62,598	64,677
Selling, general and administrative expenses		
Salaries and allowances	18,247	18,662
Welfare expenses	3,664	3,643
Provision for bonuses	3,573	3,689
Retirement benefit expenses	733	607
Distribution expenses	5,921	6,192
Rent expenses on land and buildings	1,215	1,386
Depreciation	3,348	3,353
Other	12,610	13,088
Total selling, general and administrative expenses	49,314	50,624
Operating profit	13,283	14,053
Non-operating income		
Interest income	5	0
Dividend income	876	916
Research fee income	2,171	2,184
Rental income from real estate	610	617
Share of profit of entities accounted for using equity method	171	860
Other	342	310
Total non-operating income	4,178	4,890
Non-operating expenses		
Interest expenses	1	3
Rental expenses on real estate	412	643
Other	131	62
Total non-operating expenses	545	709
Ordinary profit	16,916	18,234
Extraordinary income		
Gain on sale of investment securities	462	886
Compensation income	—	478
Other	28	0
Total extraordinary income	490	1,365
Extraordinary losses		
Loss on sale and retirement of non-current assets	1	4
Impairment losses	36	5
Expenses for business restructuring	—	922
Other	1	1
Total extraordinary losses	40	934
Profit before income taxes	17,367	18,666
Income taxes – current	10,176	9,742
Income taxes – deferred	(4,817)	(3,688)
Total income taxes	5,359	6,053
Profit	12,007	12,612
Profit attributable to non-controlling interests	2,998	3,025
Profit attributable to owners of parent	9,008	9,586

Quarterly Consolidated Statements of Comprehensive Income

(Millions of yen, rounded down to the nearest million)

	Three months ended June 30, 2024	Three months ended June 30, 2025
Profit	12,007	12,612
Other comprehensive income		
Valuation difference on available-for-sale securities	2,621	(2,257)
Deferred gains or losses on hedges	(1)	14
Remeasurements of defined benefit plans, net of tax	(79)	(153)
Share of other comprehensive income of entities accounted for using equity method	555	(411)
Total other comprehensive income	3,095	(2,808)
Comprehensive income	15,102	9,804
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	12,354	6,154
Comprehensive income attributable to non-controlling interests	2,748	3,650

(3) Notes to the Quarterly Consolidated Financial Statements

Segment Results

I. Results for the three months ended June 30, 2024

Breakdown of Net Sales and Profit by Segment

(Millions of yen, rounded down to the nearest million)

	Prescription Pharmaceutical Wholesale Business	Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business	Animal Health Products and Food Processing Raw Materials Wholesale and Related Business	Total	Adjustment (Note 1)	Amount reported in quarterly consolidated statements of income (Note 2)
Net sales						
Sales to customers	576,976	302,795	29,544	909,317	—	909,317
Intersegment sales and transfers	908	118	0	1,027	(1,027)	—
Total	577,884	302,914	29,545	910,344	(1,027)	909,317
Segment profit	5,036	7,428	684	13,150	133	13,283

Notes: 1. The adjustment of segment profit amounting to ¥133 million is the net balance of ¥754 million in inter-segment eliminations and ¥620 million in group-wide expenses that are not allocated to reportable segments.

2. Segment profit is adjusted to operating profit as reported in the quarterly consolidated statements of income.

II. Results for the three months ended June 30, 2025

Breakdown of Net Sales and Profit by Segment

(Millions of yen, rounded down to the nearest million)

	Prescription Pharmaceutical Wholesale Business	Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business	Animal Health Products and Food Processing Raw Materials Wholesale and Related Business	Total	Adjustment (Note 1)	Amount reported in quarterly consolidated statements of income (Note 2)
Net sales						
Sales to customers	599,082	315,974	30,103	945,159	—	945,159
Intersegment sales and transfers	919	73	0	993	(993)	—
Total	600,001	316,047	30,103	946,153	(993)	945,159
Segment profit	5,533	7,623	766	13,922	130	14,053

Notes: 1. The adjustment of segment profit amounting to ¥130 million is the net balance of ¥792 million in inter-segment eliminations and ¥661 million in group-wide expenses that are not allocated to reportable segments.

2. Segment profit is adjusted to operating profit as reported in the quarterly consolidated statements of income.

Notes in the Event of Significant Changes in Shareholders' Equity

None applicable

Notes Regarding Assumptions of Going Concern

None applicable

Notes Regarding Quarterly Consolidated Statements of Cash Flows

Statements of consolidated cash flows for the first three months of the fiscal year ending March 31, 2026, have not been prepared. Amounts of depreciation (including amortization of intangible assets excluding goodwill) and amortization of goodwill for the first three months of the fiscal year ended March 31, 2025, are as follows.

	(Millions of yen)	
	Three months ended June 30, 2024	Three months ended June 30, 2025
Depreciation	4,230	4,251
Amortization of goodwill	262	331

The English version of this document is a translation of the Japanese original and is provided for information purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistency or conflict between the English version and the Japanese original, the Japanese original shall prevail.